speb/financial-data huggingface dataset:
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 490301000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 1311000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 669045455.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Basic EPS: -0.02
PHARM.AS cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 54944000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -288000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Capital Expenditure Reported: -282000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 30739000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 7806000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 60093000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 107273000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -6719000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 9691000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 232000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Inventory: -1083000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -26000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Payable: -2857000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -2857000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Receivables: 5385000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 1419000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Changes In Cash: 3204000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Common Stock: 7806000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 213998000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 8323000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Current Assets: 214106000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 4233000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Current Debt: 4555000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 8788000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 77536000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Depreciation: 2582000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 2582000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 2582000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 669045455.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.02
PHARM.AS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -14719000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — EBIT: -6690000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — EBITDA: -4108000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Earnings From Equity Interest: -250000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: 232000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 1945000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — End Cash Position: 60093000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 3939000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -6719000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -56000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: 4000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 8692000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 22486000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 138863000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 24227000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Gross Profit: 70771000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Interest Expense: 5098000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 5098000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Interest Income: 604000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 604000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Interest Paid Cff: -275000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Interest Received Cfo: 737000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Inventory: 59346000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 302402000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 9691000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 5250000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 5922000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 26506000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 83849000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 110355000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -715000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 672000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 1292000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Minority Interests: 169000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -57887000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Net Debt: 28311000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income: -14719000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -14719000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -14888000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -14719000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -14719000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -11788000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -14888000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -6000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Interest Income: -4494000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 67866000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -715000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -715000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -4494000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -5970000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Net PPE: 24227000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 75135000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 18390000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 18390000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 94000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -4108000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Normalized Income: -14719000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 232000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 236000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Operating Income: -7427000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Operating Revenue: 79094000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 683931078.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 4555000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 8692000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Other Gand A: 22486000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Other Income Expense: 133000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 4424000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 1579000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 383000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Other Properties: 24227000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 47180000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Payables: 68748000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 68748000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Pretax Income: -11788000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 241000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -57887000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -6000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Receivables: 47487000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 8323000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 2582000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -715000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Research And Development: 21142000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -292801000.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 67866000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 34570000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Selling General And Administration: 57056000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Share Issued: 683931078.00
PHARM.AS cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 2576000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 213998000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 75135000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Tax Provision: 3100000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.26
PHARM.AS cash_flow (quarterly, 2025-03-31) — Taxes Refund Paid: 46000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Assets: 403181000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 297847000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Debt: 119143000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 215290000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Total Expenses: 86521000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 187891000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 189075000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 110355000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -7044000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Working Capital: 136570000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — +Operating Expense: 75249000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — +Total Revenue: 93221000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 78382000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 53327000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 491853000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 1392000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 60093000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -128000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -128000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 31953000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Capital Stock: 7821000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 92091000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 126008000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -2757000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 16955000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 11743000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Inventory: 774000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -3026000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Payable: 3888000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 3888000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Receivables: -3026000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -1390000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Changes In Cash: 25941000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Common Stock: 7821000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 239551000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 8972000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Current Assets: 245776000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 4455000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Current Debt: 5105000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 9560000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 87942000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Depreciation: -457000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 2702000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 2702000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 4694000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — EBIT: 7083000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — EBITDA: 9785000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Earnings From Equity Interest: 258000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: -240000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 6057000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — End Cash Position: 92091000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4300000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -2757000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Finished Goods: 14647000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 11615000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 25908000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 20505000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 135901000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Gross PPE: 24566000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Gross Profit: 84249000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Interest Expense: 4000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 4000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Interest Income: 659000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 659000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Interest Paid Cff: -2737000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Interest Received Cfo: 536000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Inventory: 63715000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Invested Capital: 335924000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 16955000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 5692000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 6698000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 27498000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 91268000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 118766000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -1066000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 1006000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Minority Interests: 144000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -18000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Net Debt: 4282000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income: 4694000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 4694000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 4550000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 4694000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 4694000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 7079000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 4550000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: 0.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Interest Income: 519000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 17101000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -1066000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -1066000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 519000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 0.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Net PPE: 24566000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 103650000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 31200000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 31200000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Non Current Prepaid Assets: 95000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 9785000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Normalized Income: 4694000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 11743000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -254000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Operating Income: 9000000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Operating Revenue: 93221000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 685147615.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 5105000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 25908000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Other Gand A: 20505000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Other Income Expense: -2442000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 3963000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 2023000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 1849000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Other Properties: 24566000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 33917000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Payables: 78382000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 78382000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Pretax Income: 7079000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 1046000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -18000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: 0.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: 0.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Raw Materials: 51000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Receivables: 53327000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 8972000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 2702000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -1066000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Research And Development: 23695000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Restricted Cash: 2726000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -286031000.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 17101000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 31049000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Selling General And Administration: 51554000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Share Issued: 685147615.00
PHARM.AS cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 3476000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 239551000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 103650000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Tax Provision: 2529000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.36
PHARM.AS cash_flow (quarterly, 2025-06-30) — Taxes Refund Paid: -4369000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Assets: 446259000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 330819000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Debt: 128326000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 239551000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Total Expenses: 84221000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 206708000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 200483000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 118766000.00
PHARM.AS income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 10849000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Work In Process: 49017000.00
PHARM.AS balance_sheet (quarterly, 2025-06-30) — Working Capital: 157834000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — +Operating Expense: 74465000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — +Total Revenue: 97287000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 78221000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 43606000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 507717000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 1394000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 92091000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -70000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -70000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 32574000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 7953000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 132370000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 166168000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 9933000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -349000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 32026000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Inventory: -3194000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 2034000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Payable: 3107000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 3107000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Receivables: 9094000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 11041000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Changes In Cash: 41609000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Common Stock: 7953000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 264644000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 7071000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Current Assets: 277600000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 4484000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Current Debt: 5210000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 9694000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 87914000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Depreciation: 5885000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 2726000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 2726000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 7548000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — EBIT: 20704000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — EBITDA: 23430000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest: -287000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: 287000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -1330000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — End Cash Position: 132370000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4274000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 9933000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 31956000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 25852000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 16954000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 134926000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 24992000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Gross Profit: 90216000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Interest Expense: 7946000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 7946000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Interest Income: 485000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 485000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Interest Paid Cff: -342000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Interest Received Cfo: 450000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Inventory: 67136000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 362992000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -349000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 5668000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 6673000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 28090000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 93138000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 121228000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -1096000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 1005000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -302000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income: 7548000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 7548000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 7548000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 7548000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 7548000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 12758000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 7548000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: 0.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Interest Income: -7325000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 23000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -1096000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -1096000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -7325000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -1906000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Net PPE: 24992000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 129718000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 27485000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 27485000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 95000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 23430000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Normalized Income: 7548000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 32026000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 288000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Operating Income: 15751000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Operating Revenue: 97287000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 696688239.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 5210000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: -1000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 25852000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Other Gand A: 16954000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Other Income Expense: 4333000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 2702000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 2014000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: -1000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 71000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Properties: 24992000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 33798000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Payables: 78221000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 78221000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Pretax Income: 12758000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 13277000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -302000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: 0.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: 0.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Receivables: 43606000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 7071000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 2726000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -1096000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Research And Development: 23384000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 690000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -276878000.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 23000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 34127000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Selling General And Administration: 51081000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Share Issued: 696688239.00
PHARM.AS cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 3204000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 264644000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 129718000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Tax Provision: 5209000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.26
PHARM.AS cash_flow (quarterly, 2025-09-30) — Taxes Refund Paid: -1143000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Assets: 473785000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 357782000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Debt: 130922000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 264644000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Total Expenses: 81536000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 209141000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 196185000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 121227000.00
PHARM.AS income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 15823000.00
PHARM.AS balance_sheet (quarterly, 2025-09-30) — Working Capital: 189686000.00
PHARM.AS income_statement (annual, 2025-12-31) — +Operating Expense: 309753000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — +Operating Expense: 83400000.00
PHARM.AS income_statement (annual, 2025-12-31) — +Total Revenue: 376134000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — +Total Revenue: 106500000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Accounts Payable: 8545000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 8545000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Accounts Receivable: 41767000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 41767000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -36428000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -36428000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 513257000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 513257000.00
PHARM.AS income_statement (annual, 2025-12-31) — Amortization: 6285000.00
PHARM.AS income_statement (annual, 2025-12-31) — Amortization Of Intangibles Income Statement: 6285000.00
PHARM.AS income_statement (annual, 2025-12-31) — Basic Average Shares: 712750000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 662500000.00
PHARM.AS income_statement (annual, 2025-12-31) — Basic EPS: 0.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Basic EPS: 0.01
PHARM.AS cash_flow (annual, 2025-12-31) — Beginning Cash Position: 54944000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 132370000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 27946000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 27946000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Capital Expenditure: -755000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -269000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -749000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -269000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 17720000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 17720000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Capital Stock: 8009000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Capital Stock: 8009000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 145305000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 145305000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 179101000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 179101000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1495000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1038000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 26253000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -44000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 54708000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 10707000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Inventory: -1288000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Inventory: 2215000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 902000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 1920000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Payable: 14126000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Payable: 9988000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 14126000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 9988000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Receivables: -3355000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Receivables: -14808000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Change In Working Capital: 10385000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -685000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Changes In Cash: 82454000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Changes In Cash: 11700000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Common Stock: 8009000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Common Stock: 8009000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Common Stock Equity: 277102000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 277102000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Construction In Progress: 0.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 0.00
PHARM.AS income_statement (annual, 2025-12-31) — Cost Of Revenue: 45500000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 21100000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 91312000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 91312000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Assets: 299469000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Assets: 299469000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 3369000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 3369000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Debt: 5336000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Debt: 5336000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 8705000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 8705000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Liabilities: 115791000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 115791000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Current Provisions: 1187000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Current Provisions: 1187000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Depreciation: 11216000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Depreciation: 3206000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 11216000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 3206000.00
PHARM.AS income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 9209000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 11216000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 3206000.00
PHARM.AS income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 9209000.00
PHARM.AS income_statement (annual, 2025-12-31) — Depreciation Income Statement: 2924000.00
PHARM.AS income_statement (annual, 2025-12-31) — Diluted Average Shares: 712750000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 757142857.00
PHARM.AS income_statement (annual, 2025-12-31) — Diluted EPS: 0.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.01
PHARM.AS income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 2851000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 5300000.00
PHARM.AS income_statement (annual, 2025-12-31) — EBIT: 23566000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — EBIT: 6200000.00
PHARM.AS income_statement (annual, 2025-12-31) — EBITDA: 34782000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — EBITDA: 9406000.00
PHARM.AS income_statement (annual, 2025-12-31) — Earnings From Equity Interest: 623000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: -623000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -902000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 7907000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 1235000.00
PHARM.AS cash_flow (annual, 2025-12-31) — End Cash Position: 145305000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — End Cash Position: 145305000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6703000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6703000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Financing Cash Flow: 1495000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 1038000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Finished Goods: 18214000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Finished Goods: 18214000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Free Cash Flow: 53953000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 10438000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -2345000.00
PHARM.AS income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: 0.00
PHARM.AS income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -4880000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 28819000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 28819000.00
PHARM.AS income_statement (annual, 2025-12-31) — General And Administrative Expense: 110780000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 20000000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Goodwill: 3319000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Goodwill: 3319000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 135538000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 135538000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Gross PPE: 60399000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Gross PPE: 60399000.00
PHARM.AS income_statement (annual, 2025-12-31) — Gross Profit: 330634000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Gross Profit: 85400000.00
PHARM.AS income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 491000.00
PHARM.AS income_statement (annual, 2025-12-31) — Interest Expense: 10719000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Interest Expense: 1400000.00
PHARM.AS income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 10719000.00
PHARM.AS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 1400000.00
PHARM.AS income_statement (annual, 2025-12-31) — Interest Income: 2176000.00
PHARM.AS income_statement (annual, 2025-12-31) — Interest Income Non Operating: 2176000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Interest Paid Cff: -6197000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -2843000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Interest Received Cfo: 2069000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Interest Received Cfo: 346000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Inventory: 64902000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Inventory: 64902000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Invested Capital: 375157000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Invested Capital: 375157000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Investing Cash Flow: 26252000.00
PHARM.AS cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -45000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 6703000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 6703000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Investments And Advances: 8647000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 8647000.00
PHARM.AS balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 1944000.00
PHARM.AS balance_sheet (quarterly, 2025-12-31) — Investmentsin Associatesat Cost: 1944000.00
PHARM.AS cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00